title: Prognosis of small bowel adenocarcinoma treated with Mayo or Xelox regimen: a matched case-control study from a database of 581 patients with colorectal cancer.
abstract: The purpose of this study was to compare the effects of chemotherapy on the prognosis for patients with adenocarcinoma of the small bowel (SBC) and colorectal cancer (CRC). A case-control study was conducted, comprised of 13 SBC cases treated palliatively (n=7) following surgery with capecitabine monotherapy (Xeloda) combined with oxaliplatin (Xelox), or with adjuvant 5-fluorouracil chemotherapy (Mayo) (n=6). The control group was selected from a database of 581 patients with CRC, with each SBC case being matched to 5 CRC controls. In the palliative group, response rates (RR) for SBC patients were 14%, compared to 35% for CRC patients (p=0.08). Median progression-free survival (PFS) times were 4 and 6 months (p=0.8) and median overall survival (OS) times were 8.4 and 16.4 months (p=0.9) for SBC and CRC patients, respectively. In the adjuvant group, the recurrence-free survival rates were 66 and 89% (p=0.6) after 1 year and 66 and 71% (p=0.7) after 3 years. Three-year overall survival rates were 80 and 80% (p=0.3) in the palliative group, and 80 and 66% (p=0.4) in the adjuvant group. Standard chemotherapy regimes seemed less effective on SBC than on CRC patients, and had a less favorable prognosis. However, reliable conclusions cannot be drawn from a small patient population, and multicentre studies are needed.
authors.affiliation: Department of Oncology 5073, Finsen Centre, Rigshospitalet, University of Copenhagen, DK-2100 Copenhagen, Denmark. jacoblonborg@mail.dk
authors.forename: Jacob
authors.initials: J
authors.lastname: Thomsen Lønborg
authors.forename: Adam
authors.initials: A
authors.lastname: Vilmar
authors.forename: David
authors.initials: D
authors.lastname: Mård
authors.forename: Søren
authors.initials: S
authors.lastname: Astrup Jensen
authors.forename: Jens Benn
authors.initials: JB
authors.lastname: Sørensen
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000069287:Capecitabine; D016022:Case-Control Studies; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D004338:Drug Combinations; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D007421:Intestine, Small / Q000187:drug effects* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D010071:Oxaloacetates; D010166:Palliative Care; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome